Faeth Therapeutics, a clinical-stage biotech focused on tumor metabolism, raised $25M in a financing round led by S2G Investments with participation from Khosla Ventures, Future Ventures, Digitalis Ventures, KdT Ventures, Cantos, B Capital Group and Avicella. The new capital brings Faeth's total funding to $92M.
Comments
Want to join the conversation?
Loading comments...